IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Go back to IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers| (NASDAQ: IDYA) | Delayed: 35.40 -0.83 (2.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.23 | 52 Week High | $ | |||
| Open | $36.90 | 52 Week Low | $ | |||
| Day High | $37.90 | P/E | N/A | |||
| Day Low | $35.27 | EPS | $ | |||
| Volume | 901,653 | |||||
